SunTrust analyst Charles Brady kept his Buy rating and $166 price target on Nordson after its Q2 results, saying that its adjusted margins in all three segments were better than expected even though the stock will likely trade lower on the company's lighter than expected Q3 guidance. Brady further notes that continued margin expansion is likely despite the "lumpy" core growth outlook amid increasingly more challenging comps. Longer term, the analyst adds that he is not concerned with the company's core growth rates, especially given its increasing exposure to life science and medical sectors.